CRBN and diffuse large B-cell lymphoma: Based on ibrutinib and CRBN ligand, Rao group developed PROTACs P13I and L18I, two irreversible covalent PROTACs, to degrade wide-type and C481S-mutant BTKs and suppress diffuse large B cell lymphoma (DLBCL) and MCL cells [216, 241].